Annovis Bio, Inc.’s Post

Understanding and measuring biomarkers indicative of Alzheimer's disease allows us to identify affected individuals earlier in life. This early diagnosis provides each patient with a baseline to track the progression of the disease and the effectiveness of interventions, including diet, exercise, and therapeutic treatments. Early diagnosis opens the door to timely interventions aimed at slowing the disease's progression and improving patient outcomes. Congrats C2N Diagnostics! #Alzheimers #Diagnostics

🚀 New Disease Panel from Elixirgen Scientific 🧬 We are thrilled to announce the launch of our groundbreaking human  iPSC-derived neuron disease panel from Alzheimer's Disease (AD) donors! This innovative panel includes multiple distinct AD donor and  control cell lines, providing researchers with unparalleled resources for Alzheimer's Disease research and drug development. Our panel is designed to empower researchers with advanced tools for predictive testing of drug candidates. By leveraging our transcription-factor based iPSC technology, these models recapitulate disease phenotypes for more accurate disease modeling in vitro. Discover how our iPSC-derived disease panel can accelerate your research and streamline your drug development process. Learn more: https://lnkd.in/gc6X8WKN #Biotech #Alzheimer’s #Alzheimer’sResearch #Alzheimer’sDisease #iPSC #DrugDevelopment #Biotechnology #PredictiveTesting

Discover how biomarkers are shaping the future of #Alzheimers disease detection and treatment. Quanterix is making strides in neurodegenerative research, helping identify crucial biomarkers that drive progress in drug development and patient care. Hear from David H. Wilson, VP of Clinical Strategy at Quanterix, on how this could reshape the way we approach Alzheimer’s. Read more: https://lnkd.in/gjS_hugG #AlzheimersResearch #Biomarkers #Neurodegeneration Quanterix

#Precisionmedicine is revolutionizing healthcare by customizing treatments based on individual genetic makeup, lifestyle factors, and environmental influences. Unlike traditional, one-size-fits-all methods, this approach leverages an individual's unique molecular profile to optimize treatment effectiveness, reduce the risk of adverse drug reactions, and enhance preventive care. It holds immense promise in fields such as oncology, where therapies are designed to target specific cancer mutations, as well as in the treatment of rare genetic conditions, cardiovascular diseases, and autoimmune disorders. The market for precision medicine is expanding rapidly, driven by breakthroughs in genomics, advanced data analytics, and innovations in personalized healthcare technologies. As the demand for tailored treatments—particularly for cancer and genetic disorders—grows, so does the momentum in the field. As part of our 23rd Biopharma Drug Discovery Nexus Conference, we will be hosting a #panel discussion on the latest innovations in precision medicine. If you are interested in participating or would like more information about the event, please feel free to connect with me.

"We can take this entire cohort of samples and look at how innovative, novel tests perform relative to the clinical, cognitive, neuropsych tests as well as some of these more established biomarkers. So, I see this as such a great enabler and catalyzer for the field," Dr. Laura Nisenbaum from [tag ADDF] discussing #BioHermes and what it brings to the field. Learn more here: https://lnkd.in/gHvw-wYt

🌟 IO360 starts tomorrow! Don't miss 🎤 Dr. Oscar P.'s lecture to discover how AI-driven spatial biomarkers can transform prospective patient enrollment in clinical trials. See you there! 🚀 https://hubs.li/Q02mdS5D0 #IO360 #clinicaltrials #biomarkers #spatialbiomarkers #spatialbiology #precisiononcology!

🧠 Milestone in Alzheimer’s Research: Enrollment Completed for Phase 2A ASURE Study 🧠   We are pleased to share that Treeway has officially completed patient enrollment for our Phase 2A ASURE study, which explores the potential of TW001 (oral edaravone) in treating mild-to-moderate Alzheimer’s Disease.   🌟 Why this matters: #AlzheimersDisease remains one of the toughest neurodegenerative challenges, with few effective treatments available. Treeway believes that targeting oxidative stress could offer new hope to patients and their families.   🔍 Our ASURE study is the first randomized, double-blind, placebo-controlled trial of its kind. We aim to uncover crucial insights into oxidative stress biomarkers, cognitive function, and EEG data.   💡 Supported by the Alzheimer's Drug Discovery Foundation (ADDF), we look forward to analyzing and sharing pivotal findings that could inform new treatment options in 2025.   🌐 Learn more about this exciting development by reading the full press release.   #AlzheimersDisease #Neurodegeneration #ClinicalTrials #Treeway #Biotech #Pharma #Innovation #Healthcare

Here is a recording link to my recent talk entitled, "Clinical Trials on Alzheimer's Disease: Challenges and Opportunities". On youtube.com at: https://lnkd.in/ezzvnigX Clinical trials targeting Alzheimer's disease face multifaceted challenges amidst promising opportunities. Challenges include patient recruitment, high attrition rates, and complex trial designs. Additionally, the disease's heterogeneous nature poses diagnostic and treatment challenges. However, advancements in biomarkers, precision medicine, and collaborative research efforts offer opportunities for innovative trial designs and targeted therapies. Addressing these challenges while leveraging emerging opportunities is crucial for advancing Alzheimer's disease clinical research and developing effective treatments for this devastating condition.

#MeetTheResearcher Introducing Kalina Naidoo from Wade-Martins Lab this week. Kalina is a #postdoc #researcher investigating molecular phenotypes in sporadic #ParkinsonsDisease patient derived #fibroblasts. Kalina's GSK-funded project is based on work by Michele Hu and her clinical team, that postulates that Parkinson’s Disease (PD) has 4 clusters based on their clinical symptoms (motor dysfunction presentation (unilateral or bilateral), non-motor dysfunction, disease progression, and response to levodopa treatment). Working alongside Professor Richard Wade-Martins and Dr Brent Ryan, Kalina will be investigating molecular differences in the fibroblasts (skin cells) of 100 PD patients (across all subtypes). Kalina will be focusing on elements of the cell responsible for recycling (lysosomes) and energy management (mitochondria). PD is noted by a loss of dopamine producing neurons (potentially due to energy mismanagement) in the brain and accumulation of toxic aggregated protein, alpha-synuclein (potentially due to recycling malfunction). Determining the biological underpinning of the clusters may allow for a more refined therapeutic approach, as some clusters may have stronger lysosomal dysfunction, whilst others more mitochondrial, and this informs them on what pathways to pharmacologically target, and this will hopefully lead to better outcomes for patients.

Fascinating developments in Alzheimer's treatment: I'm attending AlzeCure's live expert event on Gamma-Secretase Modulators! Excited to be virtually attending AlzeCure Pharma's upcoming event on Advances in Alzheimer's Disease Treatment: Small Molecule Gamma-Secretase Modulators as Promising Disease-Modifying Therapies. This event features esteemed Professor Henrik Zetterberg discussing cutting-edge Alzheimer's science, with a focus on recent therapeutic and diagnostic advancements. Additionally, AlzeCure's CEO and CSO will delve into their promising Alzstatin platform and its potential to combat Alzheimer's. Gamma-Secretase Modulators (GSMs) represent a novel approach in Alzheimer's treatment, and I'm particularly interested in learning more about: AlzeCure's Alzstatin platform: How it selectively targets Aβ42 oligomers while preserving other signaling pathways, unlike earlier GSIs. Clinical data from Roche's RG6289: Validating the GSM approach and showcasing its safety and efficacy potential. AlzeCure's NeuroRestore program: Exploring its potential cognitive benefits and disease-modifying effects. Join me virtually on February 19th at 3:00 PM CET (9:00 AM EST): https://lnkd.in/egyi-2RJ Let's discuss the future of Alzheimer's treatment! #Alzheimers #GSMs #AlzeCure #NeuroScience #ResearchMatters Please note: I am not affiliated with AlzeCure Pharma, but I am genuinely interested in this event and the potential of GSMs in Alzheimer's treatment.